Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Earnings for Altimmune, Inc. (ALT)
Earnings in 2023 (TTM): $-88,447,000
According to Altimmune, Inc.'s latest financial reports the company's current earnings (TTM) are $-88,447,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Altimmune, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-88,447,000 | $-88,447,000 |
| 2022 | $-84,910,000 | $-84,713,000 |
| 2021 | $-97,090,824 | $-96,171,311 |
| 2020 | $-54,461,501 | $-49,044,477 |
| 2019 | $-20,578,631 | $-20,520,131 |
| 2018 | $-45,320,946 | $-39,171,152 |
| 2017 | $-52,063,765 | $-46,425,390 |
| 2016 | $205.02 M | $193.85 M |
| 2015 | $-3,378,959 | $-3,440,705 |
| 2014 | $-9,893,649 | $-9,955,395 |
| 2013 | $-11,656,607 | $-11,718,353 |
| 2012 | $-4,724,586 | $-4,920,115 |
| 2011 | $-3,797,573,000,000 | $-3,797,573 |
| 2010 | $-34,849,277,000,000 | $-34,849,277 |
| 2009 | $-32,279,760,000 | $-32,279,760 |
| 2008 | $-36,415,113,000 | $-36,415,113 |
| 2007 | $-13,587,303 | $-13,587,303 |
| 2006 | $1.2 M | $1.02 M |
| 2005 | $325.3 K | $277.3 K |